10.1002/adsc.201800664
Advanced Synthesis & Catalysis
1-Benzylpyridin-2(1H)-one (2d):[9] Catalyst TfOH (15 mg, NMR (100 MHz, CDCl3): δ = 13.7, 22.1, 34.3, 50.5, 106.1,
10 mol %) and 2-(benzyloxy)pyridine 1d (185 mg, 1.00
121.0, 124.3, 136.0, 136.9, 139.3, 162.6 ppm.
mmol) were treated following the general procedure to
1
obtain 2d as a brown oil (133 mg, 0.72 mmol, 72%). H
(Z)-1-(Pent-2-en-1-yl)pyridin-2(1H)-one (2k): Catalyst
TfOH (15 mg, 10 mol %) and (Z)-2-(hex-2-en-1-
yloxy)pyridine 1k (177 mg, 1.00 mmol) were treated
following the general procedure to obtain 2k as a brown
NMR (400 MHz, CDCl3): δ = 5.17 (s, 2 H), 6.17 (dd, J1 =
J2 = 6.65 Hz, 1 H), 6.64 (d, J = 9.39 Hz, 1 H), 7.21–7.45
(m, 7 H) ppm; 13C NMR (100 MHz, CDCl3): δ = 52.0,
106.4, 121.4, 128.1, 128.3, 129.0, 136.5, 137.4, 139.6,
162.9 ppm.
1
liquid (133 mg, 0.75 mmol, 75%). H NMR (400 MHz,
CDCl3): δ = 1.03 (t, J = 7.46 Hz, 3 H), 2.13–2.29 (m, 2 H),
4.56–4.68 (m, 2 H), 5.46 (dtt, J = 10.70, 7.12, 7.12, 1.59,
1.59 Hz, 1 H), 5.65–5.80 (m, 1 H), 6.16 (td, J = 6.66, 1.34
Hz, 1 H), 6.57 (d, J = 9.05 Hz, 1 H), 7.21–7.39 (m, 2 H)
ppm; 13C NMR (100 MHz, CDCl3): δ = 14.1, 20.8, 45.2,
106.2, 120.9, 122.9, 136.7, 137.2, 139.3, 162.7 ppm;
1-(4-Methylbenzyl)pyridin-2(1H)-one (2e):[9] Catalyst
TfOH
(15
mg,
10
mol
%)
and
2-((4-
methylbenzyl)oxy)pyridine 1e (199 mg, 1.00 mmol) were
treated following the general procedure to obtain 2e as a
yellow oil (195 mg, 0.98 mmol, 98%). 1H NMR (800 MHz, HRMS (ESI) calcd. for C10H14NO [M+H]+ m/z 164.1070
CDCl3): δ = 2.34 (s, 3 H), 5.12 (s, 2 H), 6.14 (td, J = 6.75,
1.37 Hz, 1 H), 6.62 (dd, J1 = J2 = 9.00 Hz, 1 H), 7.16 (m,
J = 7.83 Hz, 2 H), 7.21 (m, J = 8.22 Hz, 2 H), 7.26 (dd, J =
6.65, 1.57 Hz, 1 H), 7.31 (ddd, J = 9.00, 6.65, 1.96 Hz, 1
H) ppm; 13C NMR (100 MHz, CDCl3): δ = 21.2, 51.7,
106.3, 121.3, 128.4, 129.7, 133.5, 137.2, 138.0, 139.4,
162.9 ppm.
found m/z 164.1059.
1-(3-Phenylprop-2-yn-1-yl)pyridin-2(1H)-one
(2l):[7b]
Catalyst TfOH (15 mg, 10 mol %) and 2-((3-phenylprop-2-
yn-1-yl)oxy)pyridine 1l (209 mg, 1.00 mmol) were treated
following the general procedure to obtain 2l as a brown oil
(182 mg, 0.87 mmol, 87%). 1H NMR (400 MHz, CDCl3): δ
= 4.97 (s, 2 H), 6.23 (td, J = 6.72, 1.22 Hz, 1 H), 6.51–6.64
(m, 1 H), 7.25–7.38 (m, 4 H), 7.40–7.52 (m, 2 H), 7.72 (dd,
J1 = J2 = 6.97, 1.59 Hz, 1 H) ppm; 13C NMR (100 MHz,
CDCl3): δ = 38.6, 82.1, 87.3, 106.5, 120.7, 122.1, 128.5,
129.1, 132.0, 136.0, 139.9, 162.3 ppm.
1-(4-Methoxybenzyl)pyridin-2(1H)-one (2f):[9] Catalyst
TfOH
(15
mg,
10
mol
%)
and
2-((4-
methoxybenzyl)oxy)pyridine 1f (215 mg, 1.00 mmol) were
treated following the general procedure to obtain 2f as a
brown oil (172 mg, 0.80 mmol, 80%). 1H NMR (400 MHz,
CDCl3): δ = 3.81 (s, 3 H), 5.10 (s, 2 H), 6.15 (dd, J1 = J2 =
6.48 Hz, 1 H), 6.62 (d, J = 9.29 Hz, 1 H), 6.89 (d, J = 8.56
Hz, 2 H), 7.25–7.35 (m, 4 H) ppm; 13C NMR (100 MHz,
CDCl3): δ = 51.6, 55.4, 106.3, 114.4, 121.3, 128.5, 129.9,
137.1, 139.5, 160.0, 162.9 ppm.
1-(1-Phenylethyl)pyridin-2(1H)-one (2m):[11] Catalyst
TfOH (15 mg, 10 mol %) and 2-(1-phenylethoxy)pyridine
1m (199 mg, 1.00 mmol) were treated following the
general procedure to obtain 2m as a brown oil (136 mg,
1
0.68 mmol, 68%). H NMR (400 MHz, CDCl3): δ = 1.74
(d, J = 7.09 Hz, 3 H), 6.12 (dd, J1 = J2 = 6.60 Hz, 1 H),
6.48 (q, J = 6.85 Hz, 1 H), 6.63 (d, J = 9.05 Hz, 1 H), 7.11
(d, J = 5.62 Hz, 1 H), 7.23–7.44 (m, 7 H) ppm. 13C NMR
(100 MHz, CDCl3): δ = 19.1, 52.5, 106.5, 120.8, 127.6,
128.1, 128.9, 134.4, 138.9, 140.3, 162.6 ppm.
1-(3,4-Dimethoxybenzyl)pyridin-2(1H)-one
(2g):
Catalyst TfOH (15 mg, 10 mol %) and 2-((3,4-
dimethoxybenzyl)oxy)pyridine 1g (245 mg, 1.00 mmol)
were treated following the general procedure to obtain 2g
1
as a brown oil (179 mg, 0.73 mmol, 73%). H NMR (400
MHz, CDCl3): δ = 3.83–3.91 (m, 6 H), 5.08 (s, 2 H), 6.14
(td, J = 6.66, 1.35 Hz, 1 H), 6.54–6.67 (m, 1 H), 6.78–6.96
(m, 3 H), 7.19–7.40 (m, 2 H) ppm; 13C NMR (100 MHz,
CDCl3): δ = 51.7, 56.0 (2 C), 106.2, 111.3, 117.8, 120.9,
121.2, 129.0, 137.1, 139.4, 149.1, 149.5, 162.8 ppm;
HRMS (ESI) calcd. for C14H16NO3 [M+H]+ m/z 246.1125
found m/z 246.1112.
1-(1-(4-Chlorophenyl)ethyl)pyridin-2(1H)-one
(2n):
Catalyst TfOH (15 mg, 10 mol %) and 2-(1-(4-
chlorophenyl)ethoxy)pyridine 1n (234 mg, 1.00 mmol)
were treated following the general procedure to obtain 2n
as a white solid (140 mg, 0.60 mmol, 60%). 1H NMR (400
MHz, CDCl3): δ = 1.72 (d, J = 7.09 Hz, 3 H), 6.14 (dd, J1
= J2 = 6.60 Hz, 1 H), 6.43 (q, J = 6.93 Hz, 1 H), 6.61 (d, J
= 9.05 Hz, 1 H), 7.05–7.13 (m, 1 H), 7.21–7.31 (m, 3 H),
7.31–7.40 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3): δ =
19.2, 51.9, 106.7, 120.9, 128.9, 129.1, 134.0, 134.0, 138.9,
139.0, 162.5 ppm; HRMS (ESI) calcd. for C13H13ClNO
[M+H]+ m/z 234.0680 found m/z 234.0669.
1-(4-Chlorobenzyl)pyridin-2(1H)-one (2h):[9] Catalyst
TfOH
(15
mg,
10
mol
%)
and
2-((4-
chlorobenzyl)oxy)pyridine 1h (220 mg, 1.00 mmol) were
treated following the general procedure to obtain 2h as a
1
white solid (194 mg, 0.88 mmol, 88%). H NMR (400
MHz, CDCl3): δ = 5.09 (s, 2 H), 6.15 (td, J = 6.72, 1.22 Hz,
1 H), 6.59 (d, J = 9.29 Hz, 1 H), 7.17–7.39 (m, 6 H); 13C
NMR (100 MHz, CDCl3): δ = 51.6, 106.5, 121.5, 129.2,
129.6, 134.1, 135.0, 137.2, 139.7, 162.7 ppm.
(E)-1-(4-phenylbut-3-en-2-yl)pyridin-2(1H)-one
(2o):
Catalyst TfOH (15 mg, 10 mol %) and (E)-2-((4-
phenylbut-3-en-2-yl)oxy)pyridine 1o (225 mg, 1.00 mmol)
were treated following the general procedure to obtain 2o
1
as a brown oil (178 mg, 0.79 mmol, 79%). H NMR (400
1-(Naphthalen-2-ylmethyl)pyridin-2(1H)-one
(2i):[9]
MHz, CDCl3): δ = 1.58 (d, J = 6.85 Hz, 3 H), 5.98 (ddd, J
= 6.85, 5.01, 1.83 Hz, 1 H), 6.21 (td, J = 6.72, 1.47 Hz, 1
H), 6.32 (dd, J = 16.02, 5.01 Hz, 1 H), 6.59–6.69 (m, 2 H)
7.30–7.38 (m, 4 H), 7.39–7.43 (m, 2 H) ppm; 13C NMR
(100 MHz, CDCl3): δ = 19.2, 51.2, 106.5, 121.0, 126.7,
128.3, 128.8, 129.0, 132.6, 134.2, 136.2, 139.1, 162.4 ppm.
HRMS (ESI) calcd. for C15H16NO [M+H]+ m/z 226.1226
found m/z 226.1227.
Catalyst TfOH (15 mg, 10 mol %) and 2-(naphthalen-2-
ylmethoxy)pyridine 1i (235 mg, 1.00 mmol) were treated
following the general procedure to obtain 2i as a brown oil
(212 mg, 0.90 mmol, 90%). 1H NMR (400 MHz, CDCl3): δ
= 5.32 (s, 2 H), 6.15 (dd, J1 = J2 = 6.60 Hz, 1 H), 6.67 (d,
J = 9.05 Hz, 1 H), 7.25–7.39 (m, 2 H), 7.44 (dd, J = 8.31,
1.47 Hz, 1 H), 7.47–7.56 (m, 2 H,) 7.75 (s, 1 H), 7.78–7.89
(m, 3 H) ppm; 13C NMR (100 MHz, CDCl3): δ = 52.0,
106.4, 121.3, 126.0, 126.4, 126.5, 127.3, 127.9, 128.9,
133.0, 133.4, 133.9, 137.3, 139.6, 162.9 ppm.
1-Hexyl-5-methylpyridin-2(1H)-one (2p): Catalyst TfOH
(15 mg, 10 mol %) and 2-(hexyloxy)-5-methylpyridine 1p
(193 mg, 1.00 mmol) were treated following the general
procedure to obtain 2p as a brown oil (129 mg, 0.67 mmol,
(E)-1-(Hex-2-en-1-yl)pyridin-2(1H)-one (2j):[18] Catalyst
TfOH (15 mg, 10 mol %) and (E)-2-(hex-2-en-1-
yloxy)pyridine 1j (177 mg, 1.00 mmol) were treated
following the general procedure to obtain 2j as a brown
1
67%). H NMR (400 MHz, CDCl3): δ = 0.88 (t, J = 6.36
Hz, 3 H), 1.26–1.34 (m, 6 H), 1.72 (t, J = 6.48 Hz, 2 H),
2.17 (s, 3 H), 3.88 (t, J = 7.46 Hz, 2 H), 5.96–6.08 (m, 1 H),
6.38 (s, 1 H), 7.14 (d, J = 6.85 Hz, 1 H) ppm; 13C NMR
(100 MHz, CDCl3): δ = 14.1, 21.3, 22.6, 26.4, 29.4, 31.6,
49.6, 108.6, 119.5, 136.6, 151.0, 162.8 ppm; HRMS (ESI)
calcd. for C12H20NO [M+H]+ m/z 194.1539 found m/z
194.1528.
1
liquid (127 mg, 0.72 mmol, 72%). H NMR (400 MHz,
CDCl3): δ = 0.81–0.93 (m, 3 H), 1.30–1.47 (m, 2 H), 1.96–
2.08 (m, 2 H), 4.50 (d, J = 6.85 Hz, 2 H), 5.48–5.62 (m, 1
H), 5.62–5.76 (m, 1 H), 6.15 (dd, J1 = J2 = 7.34 Hz, 1 H),
6.56 (d, J = 8.80 Hz, 1 H), 7.20–7.37 (m, 2 H) ppm; 13C
6
This article is protected by copyright. All rights reserved.